Citation for published version (APA):
Weston, C., Rana, B. M. J., & Cousins, D. J. (2018). Differential expression of functional chemokine receptors on human blood and lung group 2 innate lymphoid cells (ILC2s). Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2018.08.030
Differential expression of functional chemokine receptors on human blood and lung group 2 innate lymphoid cells (ILC2s)

Cathryn Weston, PhD, Batika M.J. Rana, PhD, David J. Cousins, PhD

PII: S0091-6749(18)31276-4
DOI: 10.1016/j.jaci.2018.08.030
Reference: YMAI 13603

To appear in: Journal of Allergy and Clinical Immunology

Received Date: 20 December 2017
Revised Date: 20 July 2018
Accepted Date: 24 August 2018

Please cite this article as: Weston C, Rana BMJ, Cousins DJ, Differential expression of functional chemokine receptors on human blood and lung group 2 innate lymphoid cells (ILC2s), Journal of Allergy and Clinical Immunology (2018), doi: 10.1016/j.jaci.2018.08.030.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Differential expression of functional chemokine receptors on human blood and lung group 2 innate lymphoid cells (ILC2s).

Cathryn Weston PhD\textsuperscript{a}, Batika M.J. Rana PhD\textsuperscript{b,c}, David J. Cousins PhD\textsuperscript{a,b}

\textsuperscript{a} Department of Infection, Immunity and Inflammation, NIHR Leicester Biomedical Research Centre - Respiratory, Leicester Institute for Lung Health, University of Leicester, Leicestershire UK;

\textsuperscript{b} MRC &Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London UK.

\textsuperscript{c} MRC Laboratory of Molecular Biology, Cambridge UK.

Corresponding authors: Dr Cathryn Weston. Email: caw38@leicester.ac.uk; Prof David J Cousins. Email: dc282@leicester.ac.uk.

Funding sources: This work was part funded by Medical Research Council (MRC) and Asthma UK (Centre Grant: G1000758), the NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London, the Midlands Asthma and Allergy Research Association (MAARA), and the NIHR Leicester Biomedical Research Centre. BMJR was funded by an MRC and Asthma UK PhD studentship. This paper presents independent research supported by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Capsule Summary: Differential expression of chemokine receptors on lymphocytes enables tissue and disease specific recruitment and activation of various lymphocytes. We have shown that human ILC2s display a different subset of functional chemokine receptors when isolated from blood or lung tissue.

Key Words: ILC2; chemokine receptor; T-cells.
Abbreviations

ILC2: group 2 innate lymphoid cell
LTi: lymphoid tissue inducer cell
NK cell: natural killer cell
Th-cell: T-helper cell
PBMCs: Peripheral blood mononuclear cells
MFI: mean fluorescence intensity
CCR: chemokine receptor (CC motif)
CXCR: chemokine receptor (CXC motif)
Main text: words

To The Editor,

Innate lymphoid cells (ILCs), primarily found at mucosal barriers, provide immediate protection against the establishment and spread of infection. ILCs have been divided into three subsets analogous to helper T (Th) cells (1): ILC1, ILC2 and ILC3. ILC2s are similar to Th2 cells and express IL-4, IL-5 and IL-13 and were initially identified as a non-T, non-B cell source of type 2 cytokines (2). They are found in the blood, gut, skin and lung where they contribute to host defence. Upon activation, ILCs rapidly produce a large quantity of cytokines and other mediators, which attract and activate other inflammatory cells. In various models of airway disease ILC2 numbers have been shown to increase with allergen challenge leading to a significant increase in type 2 inflammatory cytokines (3). Recent studies have demonstrated the existence of a complex interplay between lung epithelial cells and ILC2s that is required for asthma persistence in a mouse model. Furthermore, human studies have suggested that ILC2s provide the key link between viral infection and airway inflammation leading to asthma exacerbations (4).

ILC2s are produced from precursor cells in the bone marrow and ILC precursors have been identified in human blood, however there is debate about how ILCs populate the adult tissue with some studies indicating that they are predominantly tissue resident cells (5). An important question in ILC biology is to understand the mechanisms by which both progenitor and mature cells are recruited to the peripheral tissues such as the lung.

A significant class of cell surface receptors known to be important for immune cell migration are the chemokine receptors (6). Importantly, upregulation of key chemokines has been observed in the bronchial biopsies of asthmatic patients following allergen challenge. Due to this there has been much interest in the possibility of developing antagonists, which inhibit receptor activation, to prevent unwanted cells from being recruited to sites of inflammation such as the lung during asthma exacerbation (7). Using flow cytometry we assessed the expression of chemokine receptors on T-cells and ILC2s in both human blood and lung samples. For full methods please see online supplement. The mean data are represented in Figure 1. (11 blood donors and 5 lung samples). The pattern of receptor expression broadly agreed with previous reports for CD3+ T-cells. A smaller subset of receptors tested were readily detectable on ILC2s. These data were reflected at the RNA level as confirmed using real-time PCR probes to detect the different chemokine receptors in cDNA synthesised from RNA isolated from fresh ILC2 and T-cells (Supplemental Figure 4).

Although highly detectable on blood derived T-cells, CCR7 was not detected on ILC2s isolated from the blood or lung. CCR7 expression has previously been described on
lymphocyte precursors within the bone marrow but is only maintained on mature ILC1 and ILC3s, in particular subsets of ILCs found in the spleen and lymph nodes (8). Our data suggests that CCR7 does not play a role in the trafficking of mature ILC2s in the blood or lung tissues. CXCR5 and CXCR6 were only expressed on a small subset of blood T-cells and even fewer (<5%) lung T-cells. Furthermore, <5% of ILC2s displayed CXCR5 or CXCR6 receptor in either compartment. These results are consistent with the notion that CXCR5 is largely involved in B-cell homing and that CXCR6 is important for the retention of T-cells in the liver, and for the emigration of ILC3s from the bone marrow to the small intestine (8). CCR9, thought to direct cells to the small intestine was only detectable on around 10% of ILC2s in lung tissue.

Several receptors were significantly ($p < 0.05$) upregulated in lung tissue derived ILC2s compared to the cells isolated from the blood including CCR3 and CXCR4 (Figure 4). CCR3 in combination with CCR4 has been shown in multiple T-cell studies (7) to regulate recruitment to the lung. Furthermore, the potent inflammatory ligand (CXCL12) acting via CXCR4 appears to coordinate with CCL11 activation of CCR3 and CCL22 stimulation of CCR4 to recruit lymphocytes to the lung and generate an inflammatory reaction (7). Our data indicate that a similar mechanism could be used to activate or recruit ILC2s to the airways thereby driving inflammation.

The receptors displayed on the highest proportion of ILC2s isolated from both blood and lung tissues were CCR2, CCR4, CCR5 and CCR6. We therefore wished to determine if these receptors could be used to activate blood ILC2s via various chemokine ligands. Since ILC2s are only found as a low percentage of human PBMCs traditional chemotaxis assays would have been difficult to reliably perform. We therefore used an actin polymerization assay as a marker of receptor activation. The ligands chosen for this assay (Supplemental table 2) have all been detected in the lung (7) and were based on their receptor specificity. The stimulation time was optimized to give the largest signal window (Supplemental Figure 5). Both ILC2s and T-cells displayed ligand-dependent increases in their F-actin content following 10sec stimulation with the chemokines (Figure 2). Due to the short duration of the assay it is unlikely that these effects are through indirect activation of other immune cells. The potency for each ligand was similar between the T-cells and ILC2s however, the maximal responses were significantly ($p < 0.05$) different for all but CCL2 stimulation of CCR2, perhaps indicating differences in the number of the receptors expressed on each cell type. Comparing the response of ILC2s to each ligand (Figure 2E and Supplemental table 2) reveals that the strongest response is seen via CCR4, with CCR5 and CCR6 showing similar lower levels of activation and CCR2 an intermediary response. These values may reflect differences in receptor number on the ILC2 cell surface and may correspond to their roles in cell activity.
and tissue recruitment as it is thought that a higher receptor number is required to achieve cell
chemotaxis than. In T-cells CCR5 does not direct tissue specific recruitment but is required in
combination with different panels of receptors to enable migration (7). Therefore it may be
that initial activation of ILC2s by the more highly expressed receptors occurs before
chemotaxis is enhanced through the binding of CCR5 specific ligands

Given that a higher proportions of “activated” IL-5+, IL-13+ ILC2s have been shown to
correlate with asthma severity (9) and that mouse models of asthma demonstrate that an
increase in ILC2 number is sufficient for airway hyper responsiveness, targeting the
activation and recruitment of these cells is an attractive treatment strategy. Our data provide
new insight into the potential mechanisms by which ILC2s may be recruited or activated in
the human blood and lung, and may therefore allow rational selection of future therapeutics
targeting ILC2s in airway disease.

C Weston PhDa,
BMJ Rana PhDb,c,
DJ Cousins PhDb,a

From
a Department of Infection, Immunity and Inflammation, NIHR Leicester Biomedical
Research Centre - Respiratory, Leicester Institute for Lung Health, University of Leicester,
Leicestershire UK;
b MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, King’s College London.
c MRC Laboratory of Molecular Biology, Cambridge.

Acknowledgements

The authors wish to thank all research participants for taking part in this study and
Tracy Thornton and Sarah Glover for their assistance with volunteer recruitment. We
wish to thank Dr Adam Wright and members of the Cousins lab for helpful
discussions. We also wish to thank Prof Andrew Wardlaw, Paige Tongue, Malgorzata
Rekas, Will Monteiro, Dr Amanda Sutcliffe, Beverley Hargadon, Sarah Parker and
Hilary Marshall for their assistance in the procurement and processing of lung tissue.

5
References

1. Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J.P., Eberl, G. et al. (2013). Innate lymphoid cells — a proposal for uniform nomenclature. Nat. Rev. Immunol. 13:145–149.

2. Neill, D.R., Wong, S.H., Bellosi, A., Flynn, R.J., Daly, M., Langford, T.K. et al. (2010). Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464: 1367-1370.

3. Halim, T.Y., Steer, C.A., Mathä, L., Gold, M.J., Martinez-Gonzalez, I., McNagny, K.M. et al. (2014). Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 40: 425-435.

4. Jackson, D.J., Makrinioti, H., Rana, B.M.J., Shamji, B.W.H., Trujillo-Torralbo, M.-B., Footitt, J. et al. (2014). IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am. J. Respir. Crit. Care Med. 190: 1373-1382.

5. Gasteiger, G., Fan, X., Dikiy, S., Lee, S.Y. and Rudensky, A.Y. (2015). Tissue residency of innate lymphoid cells in lymphoid and non-lymphoid organs. Science 350: 2102-2110.

6. Griffith, J.W., Sokol, C.L. and Luster, A.D. (2014). Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32: 659-702.

7. D’Ambrosio, S., Mariani, M., Panina-Bordignon, P. and Sinigaglia, F. (2001). Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am. J. Respir. Crit. Care Med. 164: 1266-1275.

8. Soriani, A., Stabile, H., Gismondi, A., Santoni, A. and Bernardini, G. (2018). Chemokine regulation of innate lymphoid cell tissue distribution and function. Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2018.02.003. [Epub ahead of print].

9. Smith, S.G., Chen, R., Kjarsgaard, M., Huang, C., Oliveria, J.P., O’Byrne, P.M., et al. (2016). Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J. Allergy Clin. Immunol. 137:75-86.
Figure Legends

**Figure 1:** ILC2s and T-cells isolated from human lung display different chemokine receptors to those derived from blood. A) Percentage of CD3$^+$ T-cells from blood (white) and lung tissue (grey) expressing the indicated chemokine receptors. B) Percentage of ILC2s from blood (white) and lung (red) expressing the indicated chemokine receptors. Data is mean ± standard error of the mean (SEM) of 11 (PBMC) and 5 (lung) independent donors.

**Figure 2:** ILC2s respond to various chemokine receptor ligands in a dose dependent manner. Activation of A) CCR2, B) CCR4, C) CCR5, D) CCR6 receptors on ILC2s and T-cells was determined following 10s stimulation with a range of concentrations of the indicated ligands. E) Normalised ILC2 response for each receptor/ligand combination. All data is mean ± SEM from 5 independent experiments.
A. CCR2

B. CCR4

C. CCR5

D. CCR6

E. Normalised Response

- CCR2: CCL2
- CCR4: CCL17
- CCR5: CCL3L1
- CCR6: CCL20

Log[Chemokine]M vs. Normalised Response
Supplemental Methods

PBMC isolation. Peripheral blood mononuclear cells (PBMCs) were obtained from whole blood samples taken from healthy, non atopic subjects with no evidence of parasitosis recruited at University Hospitals of Leicester NHS Trust, Leicester, UK who had provided informed written consent, under ethics (REC reference number 08/H0406/189) approved by the Leicestershire, Northamptonshire and Rutland ethics committee. The heparinised blood was mixed with an equal volume of PBS and centrifuged (800g, 20min, 22°C) over Lymphoprep (Stem Cell Technologies, Cambridge UK). Isolated PBMCs were washed in PBS containing 2% FBS (Thermofisher, Paisley, UK) before counting using a haemocytometer and trypan blue stain to enable resuspension at the concentration required for further experiments as described below.

Isolation of cells from lung tissue. Lung cells were isolated from healthy lung resection material taken from patients who had provided informed written consent and were undergoing lung surgery. This material was ethically obtained at University Hospitals of Leicester NHS Trust, under the auspices of the Midlands lung tissue consortium (REC reference number 07/MRE08/42). Lung tissue bathed in DMEM containing 2% FBS was enzymatically digested for 75 mins at 37°C using hyaluronidase (0.75mg/ml, H3506, Sigma, UK) and collagenase (0.75mg/ml, C2674, Sigma) within 1h of resection. The digested tissue was filtered by sequentially passing through a 100µm then a 50µm gauze, and washed twice with DMEM containing 2% FCS (centrifuging at 230g for 8 mins, 4°C). Cell number was determined using haemocytometer and Kimura stain before washing in the absence of serum and resuspending in PBS at a concentration of 1x10^7/100µl for flow cytometric analysis as described below.

Analysis of cell surface markers by flow cytometry. For each condition tested 100µl (1x10^7 cells) of lung tissue cells were first stained for 20mins with Zombie Aqua fixable viability kit following the manufacturer’s protocol (Biolegend, London, UK). Following centrifugation (200g 10min, 4°C) the stained cells were then resuspended in 100µl brilliant violet staining buffer (Beckton Dickinson, Oxford, UK). PBMCs were adjusted to a concentration 1x10^6/100µl prior to cell surface staining. Cells were first incubated with Human Trustain (Biolegend, London, UK) at room temperature for 15min to block Fc receptors. Monoclonal antibodies: FITC conjugated lineage cocktail (α-CD2, α-CD3, α-CD14, α-CD16, α-CD19, α-CD56, α-CD235a), EF450 conjugated α-CD3 (UCHT1) (both Affymetrix, Cheshire, UK) BV605 conjugated CD123 (6H6), AF647 conjugated α-CD294 (BM16), α-CCR2 (CD192; K036C2), α-CCR4 (CD194; L291H4), α-CCR5 (CD195; JF418F1), α-CCR6 (CD196;
G034E3), \(\alpha\)-CCR7 (CD197; G043H7), \(\alpha\)-CCR9 (CD199; L053E8), \(\alpha\)-CXCR1 (CD181; 8F1/CXCR1), \(\alpha\)-CXCR3 (CD183; G025H7), \(\alpha\)-CXCR4 (CD184; 12G5), \(\alpha\)-CXCR5 (CD185; J252D4), \(\alpha\)-CXCR6 (CD186; K041E5) all PE/Cy7 conjugated, PE conjugated \(\alpha\)-CCR3 (CD193; 5E8) and \(\alpha\)-CCR10 (6588-5) (all Biolegend, London, UK) were then added for a further 20 min incubation at room temperature. For lung tissue derived cells BV785 conjugated \(\alpha\)-CD45 (HI30, Biolegend) was also added. Cells were then fixed and any red blood cells lysed through the addition of a one-step fix and lyse solution for 20 min at room temperature (Affymetrix) before centrifugation at 300g for 10 min at 4°C and resuspension in PBS supplemented with 2% FBS for acquisition on a four laser Attune NxT flow cytometer using NxT software v2.2 (Life Technologies). Compensation settings were determined using unstained cells and UltraComp eBeads™ compensation beads (Affymetrix). Following the exclusion of doublets (Supplemental Figure 1A), lymphocytes were selected based on their light scatter properties, (Supplemental Figure 1B). From the selected lymphocyte population both CD3\(^+\) T-cells (Supplemental Figure 1C) and lineage-\(\cdot\)CD123\(-\), CD294\(+\) ILC2s were identified (Supplemental Figure 1D & E). CD45 was added as an additional positive marker for identifying T-cell and ILC2 populations in lung tissue (Supplemental Figure 1G). Due to the observed bimodal distribution of expression, the CD3\(^+\) and chemokine receptor positive population was used to determine the proportion of ILC2s also displaying each chemokine receptor (Supplemental Figure 2 and 3, histograms).

**Real time PCR.** T-cells and ILC2s were sorted from PBMCs prepared as for flow cytometric analysis using a FACS ARIAIII (BD) directly into TRIZOL LS (ThermoFisher.) RNA was isolated from the purified cell populations using the miRNeasy mini kit (Qiagen), followed by DNase digestion (Thermofisher) and RNeasy minElute cleanup (Qiagen) according to the respective manufacturer’s instructions. RNA integrity was assessed using a Bioanalyser (Agilent, Edinburgh UK), according to the manufacturer’s instructions. Due to low cell number cDNA samples were synthesized and amplified using the Ovation V2 kit (NuGEN, Leek, Netherlands) as per the manufacturer’s instructions. Real-time RT-PCR was performed using TaqMan Master mix II (Thermofisher) and TaqMan probesets (all FAM-MGB) listed in Supplemental table 1. The chemokine receptor signals were compared to an 18S VIC®-MGB rRNA endogenous control (Thermofisher) Cycling conditions were as follows: 50oC for 2 mins, 95oC for 10 mins, 95oC for 15s then 60oC for 1 min for 50 cycles on a QuantStudio 5 system (Thermofisher).

**Measurement of cellular F-actin content following chemokine stimulation.** Isolated PBMCs were adjusted to 1x10\(^7\)cells/100\(\mu\)l. The ability of various recombinant chemokines
(CCL2, CCL17, CCL3L1, CCL20, all Biotechne) to activate their cognate receptor was then tested through measurement of chemokine-induced increases in the filamentous (F)-actin content of both CD3⁺T-cells and ILC2s. The method has previously been demonstrated as a marker for T-cell activation (1-2) Briefly, 100µl of cells per 10-point dose response curve were taken, Fc receptors blocked and stained with FITC conjugated CD123 and lineage cocktail, AF647 conjugated CD294, EF450 conjugated CD3 and the required PE/cy7 conjugated chemokine receptor antibodies for 20min at room temperature. Cells were washed in PBS containing 2% FBS and then resuspended in pre-warmed (37°C) RPMI 1640 (ThermoFisher) containing 2% FBS before stimulation for 10sec with the appropriate chemokine. The reaction was terminated by the addition of an equal volume of fixation buffer from the intracellular fixation and permeabilisation buffer set (Affymetrix) for 30min at room temperature. Cells were washed (1200g, 5min) 3 times with 1x permeabilisation buffer (from the intracellular fixation and permeabilisation buffer set Affymetrix) and stained with AF555 conjugated phalloidin (Life Technologies) (30min at room temperature) before washing and resuspension in PBS containing 2%FBS. Data was acquired using an Attune NxT cytometer running NxT software v2.2. Chemokine-induced changes in F-actin content were quantified as an increase in the mean fluorescence intensity (MFI) in the AF555 channel. To account for photobleaching and other non-specific effects on AF555 fluorescence the MFI for chemokine receptor positive cells was expressed as a fraction of that observed in the population not displaying the receptor for each sample.

Data analysis. Analysis of flow cytometry data was performed using FlowJo v10 (Tree star, Oregon, USA). Concentration-response curves were fitted using the three-parameter logistic equation in Graph Pad PRISM v6 (California, USA) to obtain EC₅₀ values. Statistical analysis was performed using a two-way ANOVA and Tukey’s multiple comparison test with a probability (p) <0.05 being considered significant.

Supplemental References

1. Pilette, C., Francis, J.N., Till, S.J. and Durham, S.R. (2004). CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge. *Eur. Respir. J.* 23: 876-884.
2. Slack, R.J. and Hall, D.A. (2012). Development of operational models of receptor activation including constitutive receptor activity and their use to determine the efficacy of the chemokine CCL17 at the CC chemokine receptor CCR4. *Br. J. Pharmacol.* 166: 1774-1792.
Supplemental Figure Legends

Supplemental Figure 1: Gating strategy to identify ILC2s and T-cells from human peripheral blood (A-E) and Lung (F-K). A) Total PBMCs displayed with singlet gate overlaid. B) Lymphocytes (gated cells) selected from single cell population based on light scattering properties. C) T-cells identified as the CD3+ population of single cell lymphocytes. D) Lineage–, CD294+ cells (boxed region) containing E) the CD123– ILC2s were also selected from the single cell lymphocyte population. F) Total cells displayed with singlet gate overlaid. G) Lymphocytes (gated cells) selected from single cell population based on light scattering properties. H) Live (zombie aqua–), CD45+ cells shown in gated region were selected and I) T-cells were identified as the CD3+ population J) Lineage–, CD294+ cells (boxed region) containing K) the CD123– ILC2s were also selected from the live, CD45+, single cell lymphocyte population.

Supplemental Figure 2: Chemokine receptor expression on T-cells and ILC2s in human blood. Representative flow cytometry data showing the expression of the indicated chemokine receptors on CD3+ T-cells (left) and ILC2s (right). Receptor+ gate determined using bimodal distribution observed on T-cell populations, numbers within gates indicate percentage cells.

Supplemental Figure 3: Expression of chemokine receptors on ILC2s and T-cells isolated from lung tissue. A) Representative flow cytometry data showing the expression of the indicated chemokine receptors on CD3+ T-cells (left) and ILC2s (right). Receptor+ gate determined using bimodal distribution observed on T-cell populations numbers within gates indicate percentage cells.

Supplemental Figure 4: Quantification of chemokine receptor RNA expression in T-cells and ILC2s. Relative quantities of the indicated genes were calculated relative to 18S mRNA. Plots show mean values (±SEM) for T-cells (black boxes) and ILC2s (grey boxes) sorted from PBMCs obtained from 5 independent donors.
Supplemental Figure 5: Chemokines can be used to stimulate human blood cells in a time dependent manner. A) CD3\(^+\) T-cells and B) Lineage\(^-\), CD123\(^-\), CD294\(^+\) ILC2s were identified from within a single cell, lymphocyte gate. C) CCR4 expression on T-cells (Grey) and ILC2s (Red) with gates used to select positive and negative populations overlaid. Phalloidin staining was analysed for D) CCR4\(^-\) T-cells, E) CCR4\(^+\) T-cells and F) CCR4\(^+\) ILC2s at the indicated time points. Receptor response was determined for G) chemokine receptor positive T-cells and H) chemokine receptor positive ILC2s at each time point by normalising the phalloidin mean fluorescence intensity to that observed on CCR4\(^-\) cells. (Data shown are mean ± SEM of 5 independent donors).

Supplemental Table 1: Taqman probes used in this study.

| Gene name | Probe Id          | Gene name | Probe Id          |
|-----------|-------------------|-----------|-------------------|
| CCR2      | Hs00356601_m1     | CCR7      | Hs01013469_m1     |
| CCR3      | Hs00266213_s1     | CCR10     | Hs00706455_s1     |
| CCR4      | Hs00356611_s1     | CXCR4     | Hs00237052_m1     |
| CCR5      | Hs00152917_m1     | CXCR5     | Hs00540548_s1     |
| CCR6      | Hs01890706_s1     | CXCR6     | Hs01890898_s1     |

Supplemental Table 2: Potency (pEC50) and maximal (Emax) responses observed in ILC2s and T-cells following 10s stimulation with the indicated receptor: ligand combinations. Data are mean ± SEM of experiments from at least 5 independent donors.

|         | CCR2:CCL2 | CCR4:CCL17 | CCR5:CCL3L1 | CCR6:CCL20 |
|---------|-----------|------------|-------------|------------|
| pEC50   | ILC2      | T-cell     | ILC2        | T-cell     |
|         | 8.4 ±0.2  | 8.0 ±0.2   | 9.6 ±0.2    | 9.6 ±0.2   |
| Emax    | ILC2      | T-cell     | ILC2        | T-cell     |
|         | 1.3 ±0.03 | 1.2 ±0.02  | 1.5 ±0.04***| 1.2 ±0.06**|
|         |           |            |             | 1.4 ±0.04**|
|         |           |            |             | 1.6 ±0.05  |
|         | ILC2      | T-cell     | ILC2        | T-cell     |
|         | 8.1 ±0.4  | 7.7 ±0.2   | 8.6 ±0.3*   | 7.5 ±0.1   |
|         | 1.2 ±0.06 | 1.4 ±0.04  | 1.4 ±0.04** | 1.6 ±0.05  |
